COMP <GO>
ZYME vs GENB // 10Y YIELD & FRED MACRO BETA
Zymeworks Inc. (NASDAQ) VS. Generate Biomedicines Inc. (NASDAQ) • 15-METRIC TALLY: ZYME 1
— GENB 1
■ METRIC PARITY
LAST: $28.61 (-0.35%) • MKT CAP: $2.02B
macro-sensitivity
—
LAST: $14.46 (-8.31%) • MKT CAP: $2.02B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYME VS. GENB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZYME | GENB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.20% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.71% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 38.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.85 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.9 | 59.2 | +1.70 | ZYME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.02B | $2.02B | -$769.6K | GENB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZYME REV | GENB REV | ZYME GROSS % | GENB GROSS % | ZYME FCF | GENB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $106.0M | $0 | — | — | -$34.5M | — |
| FY 2024 | $76.3M | — | — | — | -$112.0M | — |
| FY 2023 | $76.0M | — | — | — | -$118.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYME // BETA —
GENB // BETA —